Clinical Trial

Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2025 (before its estimated March 23, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study included adult patients ≥18 years old with SAA and TD-NSAA who had no HLA-matched sibling donors or were not suitable for first-line allogeneic hematopoietic stem cell transplantation due to age, complications, patient wishes, etc. After admission, they were treated with standard IST combined with rhTPO for at least 28 days. After discharge, the sequential treatment of EPAG-PFOS (with an initial dose of 150mg/d) was continued for 2 months (8 weeks), and the follow-up was conducted until the 6th month (24 weeks). It was compared with the historical cohort previously treated with IST combined with EPAG to explore the short-term efficacy and safety of this treatment regimen.
Trial Details
NCT Number NCT07001397
Lead Sponsor Peking Union Medical College Hospital
Conditions Aplastic Anemias
Enrollment 70 participants
Start Date 2025-06-23
Primary Completion 2026-03-23 (estimated)
Study Completion 2027-03-23 (estimated)
Updated on ClinicalTrials.gov 2025-06-03